Pulmonary hypertension (PH), a serious complication of sickle cell disease (SCD), causes significant morbidity and mortality. Although a recent study determined that hemin release during hemolysis triggers endothelial dysfunction in SCD, the pathogenesis of SCD-PH remains incompletely defined. This study examines peroxisome proliferatoractivated receptor g (PPARg) regulation in SCD-PH and endothelial dysfunction. PH and right ventricular hypertrophy were studied in Townes humanized sickle cell (SS) and littermate control (AA) mice. In parallel studies, SS or AA mice were gavaged with the PPARg agonist, rosiglitazone (RSG), 10 mg/kg/day, or vehicle for 10 days. In vitro, human pulmonary artery endothelial cells (HPAECs) were treated with vehicle or hemin for 72 hours, and selected HPAECs were treated with RSG. SS mice developed PH and right ventricular hypertrophy associated with reduced lung levels of PPARg and increased levels of microRNA-27a (miR-27a), v-ets avian erythroblastosis virus E26 oncogene homolog 1 (ETS1), endothelin-1 (ET-1), and markers of endothelial dysfunction (platelet/endothelial cell adhesion molecule 1 and E selectin). HPAECs treated with hemin had increased ETS1, miR-27a, ET-1, and endothelial dysfunction and decreased PPARg levels. These derangements were attenuated by ETS1 knockdown, inhibition of miR-27a, or PPARg overexpression. In SS mouse lung or in hemin-treated HPAECs, activation of PPARg with RSG attenuated reductions in PPARg and increases in miR-27a, ET-1, and markers of endothelial dysfunction. In SCD-PH pathogenesis, ETS1 stimulates increases in miR-27a levels that reduce PPARg and increase ET-1 and endothelial dysfunction. PPARg activation attenuated SCD-associated signaling derangements, suggesting a novel therapeutic approach to attenuate SCD-PH pathogenesis.
every 365 African Americans and one of every 36,000 Hispanic Americans are born with SCD, and z100,000 people are living with SCD (5) .
Pulmonary hypertension (PH), defined as an elevation of the mean pulmonary artery pressure to .25 mm Hg (6, 7) is an increasingly recognized complication of SCD that is associated with high morbidity and mortality (8) (9) (10) . Two-year mortality rates among patients with SCD and PH have been reported to be as high as 40-50% (10, 11) , and z6-10.4% of patients with SCD ultimately develop PH (12) (13) (14) . Despite the magnitude of this problem, the pathogenesis of SCD-PH remains incompletely defined. Current evidence suggests that SCD-PH, similar to other forms of PH, involves endothelial dysfunction with increased production of vasoconstrictors (e.g., endothelin-1 [ET-1]) (15) , and reduced production of vasodilators (e.g., prostacyclin [16] and nitric oxide [17, 18] ). Interactions between RBCs and endothelium may contribute to the pathogenesis of vasoocclusive crisis in SCD (19) . The release of hemoglobin and hemin during hemolysis triggers endothelial dysfunction and contributes to PH pathogenesis (20) . Recent studies in sickle cell (SS) patients demonstrate that EC adhesion molecules, including selectins and vascular endothelial cadherin, play an important role in the recruitment and binding of inflammatory cells to vascular endothelium (21) . Because SCD-PH morbidity and mortality remain unacceptably high, there is an urgent need for novel therapeutic strategies.
Mouse models of hemolysis, including the Berkeley SS mouse (18, 22) , the spherocytosis mouse (23) , and the alloimmune hemolysis mouse, develop spontaneous PH and right heart failure (18) . To further examine the pathogenesis of SCD-PH and explore novel therapeutic targets, the current study capitalized on an existing mouse model of SCD (24) (25) (26) . In this study, we used a humanized knockin mouse model of SCD (27) (the Townes model) in which mouse HbS genes are replaced with human g-and b S -hemoglobin genes and mouse a-hemoglobin genes are replaced with human a-hemoglobin genes. Because our laboratory and others have shown that stimulating peroxisome proliferator-activated receptor g (PPARg) with thiazolidinedione (TZD) ligands attenuates PH in experimental models (28) (29) (30) (31) (32) , whereas reduced PPARg expression is associated with PH pathogenesis (29, 33, 34) , we compared SS mice with littermate control (AA) mice to determine if PPARg plays an important role in SCD-associated pulmonary vascular dysfunction and PH pathogenesis.
PPARg is a ligand-activated transcription factor that belongs to the nuclear hormone receptor superfamily. The PPARg receptor is activated by a diverse spectrum of ligands that includes naturally occurring fatty acids and their metabolites, as well as synthetic TZD medications, which are currently used in this country to treat patients with type 2 diabetes. Once activated, PPARg forms a heterodimer with the retinoid X receptor and binds to PPAR response elements in the promoter region of responsive genes to increase their expression. PPARg activation can also reduce the expression of selected genes though transrepression mechanisms (35) . For example, PPARg inhibits transcription factors, such as early growth response 1 (36, 37) , Sp1 transcription factor (37, 38) , and v-ets avian erythroblastosis virus E26 oncogene homolog (ETS)1 (ETS1) (39, 40) . ETS1, a member of the ETS family of transcription factors (41) , plays an important role in proliferation, migration, vascular remodeling, apoptosis, and senescence (42) . Recent studies demonstrate that PPARg reduction increases ETS1 expression and vascular smooth muscle cell migration and proliferation (39) , whereas PPARg activation inhibits ETS1 expression and attenuates migration by inhibiting ETS1 expression (40, 43) . Furthermore, PPARg attenuates hypoxic increases in proliferative mediators (e.g., ET-1 and nicotinamide adenine dinucleotide phosphate oxidase 4), in part through inhibition of nuclear factor-kB p65 (22, 32, 44, 45) . Interestingly, mounting evidence demonstrates that pharmacological activation of PPARg attenuates pulmonary vascular cell proliferation and PH (46) , whereas loss of PPARg expression or function is associated with PH (47) . Taken together, these findings led us to postulate in the current study that: (1) chronic hemolysis in SCD stimulates loss of PPARg and increased expression of the proliferative mediator, ET-1, which contributes to PH pathogenesis; and (2) targeting PPARg with existing pharmacological ligands may represent a novel therapeutic approach in SCD to attenuate increases in proliferative mediators and SCD-PH pathogenesis.
Pathways leading to reductions in PPARg in PH continue to be defined (29, 33, 34) . We reported recently that microRNA-27a (miR-27a) plays an important role in hypoxic reductions in PPARg (37) . Evolving evidence indicates that dysregulation of microRNAs (miRNA or miR) contribute to PH pathogenesis (48) (49) (50) (51) (52) . miRNAs are endogenous, noncoding, single-stranded RNAs of z22 nucleotides that constitute a novel class of post-transcriptional gene regulators (53, 54) . miRNAs negatively regulate the expression of their target genes through translational repression or mRNA degradation (54) . Recent studies have provided compelling evidence that miRNAs regulate pulmonary vascular remodeling by controlling endothelial cell (EC) and smooth muscle cell differentiation and proliferation (48, 49, 51, 52, (55) (56) (57) . The potential role of miRNAs as master regulators of cell differentiation in physiological and pathological processes in the lung has been reviewed recently (58) (59) (60) . However, the precise posttranscriptional mechanisms by which PPARg activation regulates SCD-PH have not been defined. In the current study, we
Clinical Relevance
The current study provides novel evidence that microRNA-27a (miR-27a) is up-regulated in mice with sickle cell disease and in hemintreated human pulmonary artery endothelial cells through v-ets avian erythroblastosis virus E26 oncogene homolog 1 activation. Increases in miR-27a down-regulate peroxisome proliferator-activated receptor g (PPARg) and contribute to endothelial dysfunction. Activation of PPARg stimulates reciprocal inhibition of v-ets avian erythroblastosis virus E26 oncogene homolog 1, miR-27a and pulmonary endothelial dysfunction. We believe these findings provide the first indication that targeting PPARg activation may represent a novel therapeutic approach to attenuate sickle cell disease-pulmonary hypertension pathogenesis through modulation of microRNA levels. explored the hypothesis that hemolysis increases the levels of miR-27a to reduce PPARg expression through posttranscriptional mechanisms, leading to increased ET-1 expression, endothelial dysfunction, and PH. The current study demonstrates that SCD-related hemolysis stimulates miR-27a expression, reduces PPARg expression, and increases ET-1 in human pulmonary artery endothelial cells (HPAECs) in vitro and in the SS mouse lung in vivo. Pharmacological activation of PPARg attenuates these derangements, suggesting that therapeutic targeting of this receptor provides a novel strategy for reducing SCD-associated pulmonary endothelial dysfunction and PH.
Materials and Methods

Reagents
HPAECs were obtained from Invitrogen (Carlsbad, CA). ET-1, PPARg, ETS1, and glyceraldehyde phosphate dehydrogenase antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The following reagents were obtained from Sigma-Aldrich (St. Louis, MO): hemin, fetal bovine serum (FBS), dimethyl sulfoxide (DMSO), and methyl cellulose. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from ATCC (Manassas, VA). The PPARg ligand, rosiglitazone (RSG), was obtained from Cayman Chemical (Ann Arbor, MI).
Measurement of PH in SS Mice
The recently described Townes humanized mouse model of SCD was used in the current study (27) , and male and female SS and AA mice were examined at age 15-17 weeks, as reported (32) . All animals were given unrestricted access to water and standard mouse chow. To assess PH, SS and AA mice were subjected to measurements of right ventricular systolic pressure (RVSP) and right ventricular hypertrophy (RVH), as reported (32) . Briefly, after being anesthetized with isoflurane, RVSP was measured by introducing a 1.2-F microtip pressure transducer catheter (Transonic, Ithaca, NY) into the right internal jugular vein and advancing it to the right ventricle (RV), and RV pressures were monitored continuously for 10 minutes. RVH was assessed by dissecting the heart and calculating the ratio of the weight of the RV to the weight of the left ventricle (LV) and septum (S) [Fulton's Index, RV:(LV 1 S) weight ratio]. Selected animals were gavaged daily with 100 ml RSG (10 mg/kg/d in 100 ml 0.5% methyl cellulose) or with an equivalent volume of vehicle for 10 days, as we reported previously (32) . All experiments using mice were approved by the Institutional Animal Care and Use Committee of the Atlanta Veterans Affairs Medical Center.
Hemin-Treated HPAECs and Cell Proliferation Assay
To examine the effect of RSG on hemininduced cell proliferation, HPAECs were treated with DMSO as a control, or hemin (HEM, 5 mM), for 72 hours, as reported (61) . Hemin concentrations in this range have been measured in patients with SCD (62) . Selected HPAECs were treated with RSG (10 mM) or an equivalent volume of vehicle added directly to the culture media during the last 24 hours of hemin treatment, and cell proliferation was measured using MTT assays, as we have reported (46) .
miR-27a Down-Regulation
To confirm the role of miR-27a in alterations in PPARg expression, HPAECs (passages 3-6) were transfected with anti-miR-27a (50 nM) or an equivalent amount of scrambled anti-miR negative control using lipofectamine RNAiMax (QIAGEN, Valencia, CA). After transfection for 6 hours, media were replaced with endothelial growth medium (EGM) containing 10% FBS. HPAECs were treated with DMSO or HEM (5 mM) and then cultured for 72 hours. Alterations in miR-27a, ET-1, PPARg, platelet/endothelial cell adhesion molecule 1 (PECAM1), and E-selectin or endothelial adhesion molecule 1 (E-SEL) levels were examined using real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
PPARg Overexpression in HPAECs In Vitro
To overexpress PPARg, HPAECs were transfected with adenovirus containing a PPARg plasmid (AdPPARg, 25 multiplicity of infection) or control green fluorescent protein (GFP) plasmid, as we reported previously (63) . Six hours after transfection, adenovirus-containing medium was replaced with fresh 10% FBS EGM, and HPAECs were then treated with DMSO or HEM (5 mM) for 72 hours. Levels of miR27a, ETS1, ET-1, PPARg, PECAM-1, and E-SEL were determined by qRT-PCR.
HPAEC Transfection and RNA Interference Studies
HPAECs were transfected with scrambled or ETS1 (59-UCAGUAGAGAGAAGUGUA CGGCU TT-39, 39-UAAGUCAUCUC UCUUCACAUGCCGAA A-59) RNA interference (RNAi) duplex (10 nM) using RNAiMax transfection reagent (Invitrogen) according to the manufacturer's instructions. After transfection for 6 hours, the transfection media were replaced with EGM containing 10% FBS. HPAECs were then treated with DMSO or HEM (5 mM) for 72 hours. HPAEC lysates were then harvested and examined for ETS1, miR-27a, ET-1, and PPARg levels using qRT-PCR and Western blot assays.
miRNA and mRNA qRT-PCR Analysis
To measure miR-27a, PPARg, ETS1, ET-1, E-SEL, and PECAM1 levels in HPAECs or SS mouse lungs, small RNAs (,200 nt) and large RNAs (.200 nt) were isolated using the mirVana kit (Invitrogen). The levels of miR-27a expression were analyzed by qRT-PCR using the QIAGEN miRNA primer assay according to the manufacturer's instructions. RNU6B (miRNA) was used as an endogenous control. PPARg, ETS1, ET-1, PECAM1, and E-SEL mRNA levels in the same sample were determined and quantified using specific mRNA primers, as described previously (46) . Levels of 9S mRNA were used as an endogenous control.
Western Blot Analysis
After treatment with RSG or vehicle, protein homogenates from mouse lungs or hemintreated HPAECs were subjected to Western blot analysis, as reported (46 
Statistical Analysis
For all measurements, data are presented as mean 6 SE. All data were analyzed using analysis of variance. Post hoc analysis used the Student-Newman-Keuls test to detect differences between specific groups. In studies comparing only two experimental groups, data were analyzed with Student's t test to determine the significance of treatment effects. The level of statistical significance was taken as P , 0.05. Statistical analyses were performed using GraphPad Prism, Version 5.0 software (LaJolla, CA).
Results
Townes SS Mice Develop PH and RVH Spontaneously
Because PH is an important complication of SCD (64, 65) and is associated with an increased mortality risk (12-14), we measured RVSP and RVH in SS and AA mice. As illustrated in Figure 1 , Townes SS mice of either sex at 15-17 weeks of age spontaneously developed PH ( Figure 1A ) and RVH ( Figure 1B ). As reported previously (27) , Townes SS mice showed decreased hematocrit values compared with AA mice ( Figure 1C ), whereas no differences in heart rate were observed between AA and SS mice ( Figure 1D ). To evaluate pulmonary vascular remodeling in SS and AA mice, a-smooth muscle actin-stained lung sections were used, and the number of muscularized vessels per square millimeter was counted. As illustrated in Figure 1E , pulmonary vascular remodeling was increased in SS compared with AA lungs. 
Alterations in PPARg and ET-1 in SS Mice and Hemin-Treated HPAECs
Because mounting evidence demonstrates that PPARg activation attenuates PH (46) , whereas loss of PPARg expression is associated with PH (47), we examined PPARg levels in SCD-PH. As illustrated in Figure 2A , PPARg mRNA and protein levels were reduced in SS mouse lungs. Because ET-1 levels are increased in the plasma of patients with SCD (66-68) and because PPARg negatively regulates ET-1 (46), we measured ET-1 mRNA and protein levels in these same models. As expected, ET-1 expression was increased in SS compared with AA lungs (see Figure  E1A in the online supplement). Circulating hemin levels are increased in SCD and they contribute to vascular endothelial dysfunction (69, 70) , and plasma hemin concentrations in patients with SCD were z4.2 mM compared with 0.2 mM in healthy control subjects (62) . Hemin, released into the circulation during hemolysis, causes inflammation, oxidative damage, and endothelial dysfunction and contributes to SCD-PH pathogenesis (71) . Furthermore, plasma cell free hemin levels are elevated in Townes SS mice (72) and they contribute to endothelial barrier dysfunction (73) . Thus, we examined the dose-dependent (0-10 mM) effects of hemin on HPAECs ( Figure E2 ).
Treatment with hemin (5 mM) was sufficient to reduce PPARg mRNA and protein levels ( Figure 2B ) and increase HPAEC ET-1 mRNA and protein levels ( Figure E1B ). Hemin treatment was therefore selected to further model SCDinduced endothelial signaling pathways in vitro.
To examine the role of endothelial dysfunction in SCD-PH pathogenesis, we examined levels of markers of endothelial dysfunction, including E-SEL ( Figure E3A ) and PECAM1 ( Figure E3B ). Each of these markers of endothelial dysfunction was increased in the lungs of SS mice compared with those of AA mice. In parallel, hemin treatment was sufficient to increase HPAEC mRNA and protein levels of these same markers of endothelial dysfunction in vitro ( Figures E3C and E3D ).
miR-27a Is Increased in SS Mice and Hemin-Treated HPAECs
To examine potential miRNAs that negatively regulate PPARg, a bioinformatics approach using multiple prediction algorithms (miRBase, PicTar, and TargetScan v6.1) was used to identify binding sites for miRNAs in the 39UTR of PPARg. This analysis indicated miR-27a/b, miR-130a/b, miR-301a/b, and miR-454 as potential regulators of PPARg. Samples from SS and AA mouse lungs or hemintreated HPAECs were used to screen for alterations in these miRNAs. As illustrated in Figure 3A , of the miRNAs that were examined and predicted to regulate PPARg, miR-27a was increased in SS mouse lung and miR-130b, miR-301a/b, and miR-454 were selectively increased in SS mouse lung ( Figure E4A ). As illustrated in Figure 3B , compared with control conditions, hemin increased the levels of miR-27a and miR-27b only in HPAECs in vitro ( Figure  E4B ). Because increased levels of miR-27a are predicted to reduce PPARg, and because miR-27a reduced lung PPARg levels in a hypoxia-induced model of PH (37), subsequent studies focused on miR-27a in SS mouse lung and hemin-treated HPAECs.
miR-27a Inhibition
We have reported previously that 50 nM anti-miR-27a reduced miR-27a levels by 50% and increased PPARg levels in HPAECs (37) . To confirm the role of miR-27a in hemin-induced reductions in PPARg and increases in ET-1 and endothelial dysfunction, loss-of-miR-27a function was accomplished by transfecting HPAECs with an miR-27a inhibitor. Anti-miR-27a increased PPARg levels in control HPAECs and attenuated reductions in PPARg levels in hemin-treated HPAECs ( Figure 3C ). Anti-miR-27a also lowered HPAEC ET-1 mRNA levels in control cells and attenuated hemin-stimulated increases in ET-1 mRNA ( Figure 3D ). In addition, inhibition of miR-27a attenuated hemininduced increases in E-SEL and PECAM1 mRNA levels ( Figures 3E and 3F ).
ETS1 Knockdown Attenuates
Increases in miR-27a and ET-1
To further examine the mechanisms underlying increases in miR-27a in SS mouse lungs and hemin-treated HPAECs, in silico analysis of the miR-27a promoter using PuTmiR software was performed (74 
PPARg Regulates miR-27a and ET-1 Expression and Endothelial Dysfunction
We demonstrated previously that miR-27a and PPARg were mutually repressive in the hypoxic pulmonary vasculature (37) . To further determine if alterations in PPARg expression are sufficient to regulate miR-27a, ET-1, and endothelial dysfunction, AdPPARg expression construct was used to examine PPARg gain of function in hemin-induced signaling. As shown in Figure E6 , AdPPARg caused large and Anti-miR-27a reduces endothelin-1 (ET-1) and markers of endothelial dysfunction and increases PPARg expression in hemin-treated HPAECs. (A) Whole lung homogenates were collected from SS and AA mice. qRT-PCR was performed on lung tissue for miR-27a predicted to regulate PPARg expression. Each bar represents the mean miR-27a level 6 SE relative to RNA, U6B small nuclear (RNU6B) and normalized to control values. *P , 0.05 versus AA (n = 3-6). (B) HPAECs were treated with dimethyl sulfoxide vehicle (CON) or hemin (HEM, 5 µM) for 72 hours. *P , 0.05 versus CON (n = 3-6). HPAEC miR-27a was isolated and subjected to qRT-PCR analysis together with RNU6B. Each bar represents the mean miR-27a level 6 SE relative to RNU6B and normalized to control values. *P , 0.05 versus CON (n = 3-6). (C-F) HPAECs were treated with either scrambled or 50 nM anti-miR-27a for 6 hours and then treated with dimethyl sulfoxide vehicle (CON) or hemin (HEM, 5 µM) for 72 hours. HPAECs were then collected, and mRNAs were isolated. qRT-PCR was performed for (C) PPARg, (D) ET-1, (E) endothelial adhesion molecule 1 (E-SEL), and (F) platelet/endothelial cell adhesion molecule 1 (PECAM1) levels. Each bar represents the mean mRNA level 6 SE relative to ribosomal S9 (9S RNA) expressed as fold change versus CON. *P , 0.05 versus CON; 1 P , 0.05 versus HEM (n = 6-9).
dose-dependent increases in HPAEC PPARg protein levels. As shown in Figure 5 , AdPPARg at 25 multiplicity of infection increased PPARg ( Figure 5A ) and decreased miR-27a ( Figure 5B ) and ETS1 ( Figure 5C ) mRNA levels in control cells. PPARg overexpression also prevented hemin-induced reductions in HPAEC PPARg and increases in miR-27a and ETS1 levels. Similarly, PPARg overexpression reduced ET-1, E-SEL, and PECAM1 mRNA levels in control HPAECs and attenuated hemin-induced increases in mRNA levels of these markers of endothelial dysfunction ( Figures 5D-5F ).
PPARg Activation Attenuates Increases in miR-27a and ETS1 Levels and Restores PPARg in SS Mouse Lungs and Hemin-Treated HPAECs
Because PPARg levels were reduced in the lungs of SS mice, and because, as we have reported previously, pharmacological PPARg activation attenuates increases in miR-27a levels in the lung and attenuates hypoxia-induced PH (37), we sought to examine the impact of PPARg activation on miR-27a levels in SS mouse lungs and hemin-treated HPAECs. As shown in Figure 6 , consistent with Figures 2 and 3 , miR-27a was significantly increased in SS mouse lungs, whereas PPARg levels were significantly reduced. Treating mice with the PPARg ligand, RSG, using a regimen that attenuated hypoxia-induced PH (32), attenuated increases in miR-27a and ETS1 mRNA levels and restored PPARg levels in SS mouse lungs (Figures 6A-6C) . Similarly, in HPAECs treated with hemin for 72 hours, treatment with RSG during the last 24 hours attenuated hemin-induced increases in miR-27a and ETS1 and decreases in PPARg (Figures 6D-6F ). To further examine phenotypic changes in hemin-treated HPAECs and the effect of RSG on hemin-induced cell proliferation, HPAEC proliferation was measured with MTT assays. Figure E7 shows that hemin significantly increased HPAEC proliferation and that RSG treatment attenuated hemin-induced HPAEC proliferation. Taken together, the findings in Figures 3-5 provide compelling evidence that miR-27a down-regulates PPARg to stimulate ET-1 expression and endothelial dysfunction, and that activation of PPARg can negatively regulate miR-27a in these conditions.
Discussion
In the current study, we demonstrate, we believe for the first time, that (1) the Townes humanized SS mouse model spontaneously develops PH, RVH, and pulmonary vascular remodeling, (2) PPARg levels are reduced in lungs from SS mice and in hemin-treated HPAECs, and (3) miR-27a levels are increased in SS mouse lung and in hemin-treated HPAECs through pathways involving the ETS1 transcription factor. Furthermore, reductions in PPARg promote increased expression of ET-1 and markers of endothelial dysfunction in vivo and in vitro. Activation of PPARg with the pharmacological ligand RSG or with adenoviral-mediated PPARg overexpression attenuates these derangements, suggesting that therapeutically targeting PPARg provides a novel strategy for reducing SCD-associated pulmonary endothelial dysfunction and PH ( Figure 7) .
ET-1 is elevated in both patients with SCD and those with PH and plays a key role in the pathophysiology of SCD and PH. Although several potential therapeutic strategies have been investigated in SCD-PH, none have significantly affected SCD-PH outcomes (11, (75) (76) (77) (78) (79) . The importance of ET-1 in the pathogenesis of SCD-PH is well established (80) (81) (82) (83) . ET-1 causes endothelial dysfunction and stimulates vasoconstriction and migration and proliferation of pulmonary vascular wall cells in PH (81, 84) . However, in clinical trials in SCD-PH, the ET-1 receptor antagonist, bosentan, failed to significantly reduce pulmonary vascular resistance (85) . Thus, despite existing evidence that ET-1 plays an important pathophysiological role in SCD-PH pathogenesis, new therapeutic strategies that regulate ET-1 as well as other pathways involved in SCD-PH may lead to more effective and widely applicable therapeutic approaches for SCD-PH. We demonstrated previously that PPARg ligands favorably modulate several components of the ET-1 signaling pathway (46) and also attenuate other proliferative signaling pathways including nicotinamide adenine dinucleotide phosphate oxidase 4 (32), platelet-derived growth factor (32) , and thrombospondin-1 (86) in hypoxiainduced PH pathogenesis. These findings indicate that the therapeutic potential of targeting PPARg in SCD-PH merits additional evaluation and led us to the current study.
Chronic hemolysis in SCD stimulates steady-state inflammation (87, 88) through subclinical vascular endothelial injury and transient vasoocclusive events (70, 89) . The vascular endothelium in the lung and other organs senses these SCD-related stimuli including hypoxia, ischemia-reperfusion, hemoglobin, and hemin. Studies in SS mice demonstrate a role for adhesion molecules in the interaction of erythrocytes with the endothelium (22, (90) (91) (92) (93) . Furthermore, adhesion molecules are increased in SCD and are associated with PH and mortality (21) . Current evidence suggests that SCDrelated hemolysis and its byproducts, hemoglobin and hemin, induce endothelial dysfunction and PH in SCD. We postulated that these hemolysis-induced derangements in endothelial function play an important role in overall pulmonary vascular dysfunction, transducing signals from the blood to other cellular compartments of the vascular wall (72, 73) . Our findings are consistent with these concepts and demonstrate that endothelial adhesion molecules, including E-SEL and PECAM1, are increased significantly in the lungs of SS mice and in hemin-treated HPAECs ( Figure E3 ). Hemin triggers vasoocclusion through increases in and activation of these adhesion molecules (90) . The current studies demonstrate that PPARg activation attenuates endothelial dysfunction in the SS mouse lung and in hemin-treated HPAECs (Figures 5 and 6 ), supporting the concept that therapeutic targeting of this receptor provides a novel strategy for reducing SCD-PH. In addition, unpublished studies by our group indicate that PPARg activation may also exert direct and beneficial effects on the myocardium in experimental models of PH.
We reported recently that hypoxiainduced PH was associated with reductions in PPARg, and that activating the PPARg receptor attenuates hypoxia-induced reductions in PPARg in mouse lungs and HPAECs (32, 46) . The current study extends these observations by providing novel evidence that PPARg is reduced in the lungs of SS but not AA mice. Because treatment with pathobiologically relevant concentrations of hemin was sufficient to reduce PPARg in HPAECs in vitro (Figure 1 ), these findings suggest that products of intravascular hemolysis trigger these reductions in PPARg. Furthermore, our findings indicate that PPARg activation restores PPARg in SS mouse lung and in hemin-treated HPAECs (Figures 5 and 6 ), supporting the concept that stimulating PPARg may provide a novel therapeutic strategy in SCD-PH.
We demonstrated previously that hypoxic exposure sufficient to induce PH in vivo and pulmonary artery EC proliferation in vitro increased miR-27a and reduced PPARg (37) . Furthermore, PPARg activation attenuated hypoxiainduced reductions in PPARg by attenuating hypoxia-induced increases in miR-27a levels. Emerging evidence supports the role of miRNAs in PH pathogenesis (94) . Both miR-648 (95) and miR-199a2 (96) were reported to contribute to SCD pathogenesis in the Berkeley SS mouse. Our findings extend these observations to suggest that miR-27a also contributes to SCD-PH. Levels of miR-27a were increased in the lungs of SS mice and hemin-treated HPAECs (Figure 3 ). Anti-miR-mediated inhibition of miR-27a (Figure 3) , activation of PPARg with RSG (Figure 6 ), or overexpression of PPARg ( Figure 5 ) attenuated increases in miR-27a levels in SS mouse lung and HPAECs. These results provide novel evidence that PPARg activation suppresses increases in miR-27a in SCD, which is consistent with previous reports of the repressive effect of PPARg activation on miR-27a under hypoxic conditions (37) .
To further explore the mechanisms for increases in miR-27a levels in SCD, we performed an in silico analysis of the upstream promoter region of miR-27a and identified putative ETS1 binding sites. Recent studies reported that hemin increases ETS1 mRNA levels in human erythroleukemic cell lines (97) , that dominant-negative loss of PPARg function increases ETS1 expression (39) , and that PPARg activation attenuates ETS1 activity (36) . Therefore, to further investigate whether ETS1 activates the miR-27a promoter in SCD and whether it might also be regulated by PPARg, we examined the effects of PPARg activation on ETS1 in SS mouse lung and in hemin-treated HPAECs. The importance of ETS1 was supported by evidence that small interfering RNAmediated ETS1 depletion attenuated hemin-induced (1) increases in HPAEC miR-27a and ET-1 and (2) decreases in PPARg expression (Figure 4 ). Taken together, these novel findings indicate that hemin and perhaps other stimuli in SCD can activate ETS transcription factors to increase miR-27a levels. As reported previously (37), miR-27a reduces PPARg, which attenuates ET-1 levels and prevents endothelial dysfunction. Because of the mutually repressive relationship between miR-27a and PPARg (37), our findings suggest that stimulating the PPARg receptor with exogenous PPARg ligands can reverse pathogenic programs of gene expression in SCD. These findings highlight a previously unrecognized pathobiological cascade in SCD that may be amenable to therapeutic intervention.
This study has several important limitations. First, although the current study demonstrates that hemin increases ETS1 and miR-27a levels, it does not directly address how hemin increases ETS1 levels. ETS1 knockdown attenuated hemininduced increases in miR-27a levels and increased PPARg mRNA and protein levels in HPAECs. These findings indicate that ETS1 stimulates miR-27a expression in HPAECs and suggest that PPARg activation could attenuate ETS1 and miR-27a promoter activity through transrepression. Therefore, additional studies will be required to further define how hemin directly stimulates ETS1. Second, although discordant patterns of miRNA expression have been reported in experimental rodent models and in human PH (98) , reductions in PPARg have been reported in several experimental models of PH (28, 30, 32, 33, 46, 99) , in human PAH lung tissue (33) , and in pulmonary artery ECs isolated from patients with idiopathic pulmonary arterial hypertension (37) . These findings suggest that common mechanisms that regulate PPARg during PH pathogenesis in multiple models and species merit additional investigation and qRT-PCR was performed on AA and SS lung tissues. Lung miR-27a levels are expressed relative to RNU6B and normalized to control values. Each bar represents the mean 6 SE. *P , 0.05 versus AA/2RSG; 1 P , 0.05 versus SS/2RSG, (n = 3-6). Lung (B) PPARg and (C) ETS1 mRNA levels were measured with qRT-PCR and expressed relative to lung 9S mRNA levels. Each bar represents the mean PPARg and ETS1 mRNA level 6 SE expressed as fold change versus AA/2RSG. *P , 0.05 versus AA/2RSG; 1 P , 0.05 versus SS/2RSG (n = 3-6). HPAECs were treated with dimethyl sulfoxide vehicle (CON) or hemin (HEM, 5 mM) for 72 hours. During the final 24 hours of hemin exposure, selected HPAECs were treated with or without RSG (10 mM). HPAECs were then collected, and miRNAs or total RNAs were isolated. qRT-PCR was performed for (D) miR-27a, (E) PPARg, and (F) ETS1 levels. Each bar represents the mean 6 SE miR-27a, PPARg, or ET-1 level relative to RNU6B or 9S as indicated. *P , 0.05 versus CON/2RSG; 1 P , 0.05 versus HEM/2RSG (n = 3-6). (101). Thus, although the current study, together with other reports, suggests therapeutic benefits of pharmacological PPARg activation in PH, the potential of this therapeutic strategy will require additional study and more refined pharmacological tools that activate PPARg without causing adverse effects.
Conclusions
To our knowledge, the current study of SCD-PH pathogenesis provides the first evidence that miR-27a reduces PPARg expression and increases ET-1 expression and endothelial dysfunction through posttranscriptional mechanisms in vivo and in vitro. Furthermore, this study provides novel evidence that ETS1 mRNA levels were increased in SS mouse lungs and in hemin-treated HPAECs and that ETS1 loss of function was sufficient to attenuate hemin-induced increases in HPAEC miR-27a and ET-1 and decreases in PPARg expression. These results suggest that targeting PPARg activation may represent a novel therapeutic approach in SCD-PH pathogenesis. n
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PPARγ ligands ETS1 SCD-PH Figure 7 . Schema of putative pathways increasing miR-27a and reducing PPARg that increase ET-1 and endothelial dysfunction in sickle cell disease (SCD). The current findings suggest that products of hemolysis in SCD, such as hemin, activate the transcription factor ETS1 to stimulate the expression of miR-27a. Increases in miR-27a reduce PPARg, leading to increased ET-1, endothelial dysfunction, and pulmonary hypertension (PH). Stimulation of PPARg with pharmacological ligands such as RSG attenuates increases in miR-27a and downstream ET-1 levels and endothelial dysfunction, suggesting that this pathway may provide an opportunity for new therapeutic targeting and intervention in SCD-PH.
